MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma

Carcinogenesis

Volumn 33, Issue 5, 2012, Pages 1113-1120

  Wang, Wen ^a   Zhao, Lan Juan ^a   Tan, Ye Xiong ^a   Ren, Hao ^a   Qi, Zhong Xian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D3; MICRORNA; MICRORNA 138; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL CYCLE ARREST; CELL VIABILITY; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84860485917     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs113     Document Type: Article

References (52)

1. Parkin, D.M. et al. (2002) Global cancer statistics. CA Cancer J. Clin., 55, 74-108.
2. Aravalli, R.N. et al. (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology, 48, 2047-2063.
3. Nelson, K.M. et al. (2008) MicroRNAs and cancer: past, present, and potential future. Mol. Cancer Ther., 7, 3655-3660.
4. Bartel, D.P. et al. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
5. He, L. et al. (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet., 5, 522-531.
6. Calin, G.A. et al. (2006) MicroRNA signatures in human cancers. Nat. Rev. Cancer, 6, 857-866.
7. Esquela-Kerscher, A. et al. (2006) Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer, 6, 259-269.
8. Ashburner, M. et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet., 25, 25-29.
9. Dupuy, D. et al. (2007) Genome-scale analysis of in vivo spatiotemporal promoter activity in Caenorhabditis elegans. Nat. Biotechnol., 25, 663-668.
10. Schlitt, T. et al. (2003) From gene networks to gene function. Genome Res., 13, 2568-2576.
11. Kanehisa, M. et al. (2004) The KEGG resource for deciphering the genome. Nucleic Acids Res., 32, D277-D280.
12. Yi, M. et al. (2006) WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics, 7, 30.
13. Draghici, S. et al. (2007) A systems biology approach for pathway level analysis. Genome Res., 17, 1537-1545.
14. Whittaker, S. et al. (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 29, 4989-5005.
15. Min, L. et al. (2011) Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin. Cancer Biol., 21, 10-20.
16. Mishra, L. et al. (2009) Liver stem cells and hepatocellular carcinoma. Hepatology, 49, 318-329.
17. Takigawa, Y. et al. (2008) Wnt signaling in liver cancer. Curr. Drug Targets, 9, 1013-1024.
18. Braconi, C. et al. (2008) MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology, 47, 1807-1809.
19. Ladeiro, Y. et al. (2008) MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology, 47, 1955-1963.
20. Mott, J.L. (2009) MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology, 50, 630-637.
21. Shen, Q.L. et al. (2010) Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol. Cancer, 9, 227-239.
22. Sakurai, K. et al. (2011) MicroRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feed back loop in a variety of human cancers. Cancer Res., 75, 1680-1689.
23. Port, M. (2011) Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol. Cancer, 10, 52-59.
24. Kim, T.H. et al. (2010) Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology, 57, 734-743.
25. Li, M. et al. (2009) Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell, 16, 533-546.
26. Luo, H. et al. (2009) Down-regulated miR-9 and miR-433 in human gastric carcinoma. J. Exp. Clin. Cancer Res., 28, 82-90.
27. Oberg, A.L. (2011) miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One, 6, e20465.
28. Zhu, S. et al. (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res., 18, 350-359.
29. Tsai, W.C. et al. (2009) MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology, 49, 1571-1582.
30. Bai, S. et al. (2009) MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem., 284, 32015-32027.
31. Tsang, T.Y. et al. (2011) P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells. Apoptosis, 16, 524-535.
32. Wang, C.M. et al. (2011) miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 411, 586-592.
33. Fang, J.H. et al. (2011) MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology, 54, 1729-1740.
34. Arzumanyan, A. et al. (2011) Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res., 71, 3701-3708.
35. Yoon, S.O. et al. (2011) Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Hum. Pathol., 42, 1391-1400.
36. Gramantieri, L. et al. (2009) MicroRNA-221 targets Bmf in hepatocellular carcinoma and Correlates with tumor multifocality. Clin. Cancer Res., 15, 5073-5081.
37. Li, W. et al. (2008) Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer, 123, 1616-1622.
38. Chiang, C.W. et al. (2010) PKC alpha mediated induction of miR-101 in human hepatoma HepG2 cells. J. Biomed. Sci., 17, 35.
39. Jiang, L. et al. (2010) Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int. J. Cancer, 127, 505-512.
40. Song, T. et al. (2011) MiR-138 suppresses expression of hypoxia-inducible factor 1 (HIF-1) in clear cell renal cell carcinoma 786-O cells. Asian Pac. J. Cancer Prev., 12, 1307-1311.
41. Liu, X. et al. (2011) MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem. J., 440, 23-31.
42. Jin, Y. et al. (2011) Molecular characterization of the microRNA-138-Foslike antigen 1 (FOSL1) regulatory module in squamous cell carcinoma. J. Biol. Chem., 286, 40104-40109.
43. Jiang, L. et al. (2011) Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma. Hum. Genet., 129, 189-197.
44. Lin, J. et al. (2001) Cdk6-cyclin D3 complex evades inhibition by inhibitor proteins and uniquely controls cell's proliferation competence. Oncogene, 20, 2000-2009.
45. Liu, Q. et al. (2008) The miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res., 36, 5391-5404.
46. Grillo, M. et al. (2006) Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res. Treat., 95, 185-194.
47. Wang, G.L. et al. (2006) Cyclin D3 maintains growth-inhibitory activity of C/EBPalpha by stabilizing C/EBPalpha-cdk2 and C/EBPalpha-Brm complexes. Mol. Cell. Biol., 26, 2570-2582.
48. Liu, Q. et al. (2008) miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res., 36, 5391-5404.
49. Lin, J. et al. (2001) Cdk6-cyclin D3 complex evades inhibition by inhibitor proteins and uniquely controls cell's proliferation competence. Oncogene, 20, 2000-2009.
50. Renate, F. et al. (2004) Cdk6-cyclin D3 activity in murine ES cells is resistant to inhibition by p16INK4a. Oncogene, 23, 491-502.
51. Lu, J. et al. (2011) MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res., 71, 225-233.
52. Wang, J. et al. (2011) Enhanced expression of cyclins and cyclin-dependent kinases in aniline-induced cell proliferation in rat spleen. Toxicol. Appl. Pharmacol., 250, 213-220.